Interim Editor of In Vivo
Jo Shorthouse is the Interim Editor of In Vivo. She has contributed to various Pharma Intelligence publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence’s Commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Pharma Intelligence and In Vivo teams.
Latest From Jo Shorthouse
Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.
Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market.
Publisher’s Spotlight: Citeline, the publisher of In Vivo, is to merge with fellow pharmaceutical solutions provider Norstella.
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.